Fig. 1 · Structure
Documents & Downloads
Larotinib
Tyrosine Kinase Inhibitor
Larotinib is a potent orally active tyrosine kinase inhibitor (TKI) primarily targeting the epidermal growth factor receptor (EGFR) with an IC50 of 0.6 nM. This compound exhibits broad-spectrum kinase inhibition, making it a valuable tool in cancer research, particularly in studies focused on EGFR-mutant tumors. Its efficacy in inhibiting cellular proliferation and survival pathways underlines its potential utility in therapeutic applications targeting various oncogenic signaling cascades.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 1438072-11-7 |
| Applications | Tyrosine Kinase Inhibitor |
| Formula | C24H26ClFN4O4 |
| Molecular Weight | 488.94 |
| SMILES | COC(C(OCCCN1C[C@]2([H])[C@](OCCO2)([H])C1)=C3)=CC4=C3C(NC5=CC(Cl)=C(C=C5)F)=NC=N4 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.